‌

US Patent 10052320 Substituted quinoxalines as FGFR kinase inhibitors

Patent 10052320 was granted and assigned to Astex Therapeutics Limited on August, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Astex Therapeutics Limited

0

Current Assignee

Astex Therapeutics Limited

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Valerio Berdini0

Olivier Alexis Georges Querolle0

Steven John Woodhead0

Virginie Sophie Poncelet0

Christopher William Murray0

Gilbert Ebai Besong0

Gordon Saxty0

Lieven Meerpoel0

Date of Patent

August 21, 2018

0

Patent Application Number

150141560

Date Filed

February 3, 2016

0

Patent Citations Received

US Patent 11918576 Combination of an FGFR inhibitor and a CMET inhibitor

0

US Patent 10272087 Pteridines as FGFR inhibitors

US Patent 10421747 Quinoxaline derivatives useful as FGFR kinase modulators

0

US Patent 10478494 FGFR/PD-1 combination therapy for the treatment of cancer

US Patent 10519137 Pyrazolyl quinoxaline kinase inhibitors

US Patent 11542247 Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer

US Patent 10716787 Combinations

US Patent 10736900 Combinations of an FGFR inhibitor and an IGF1R inhibitor

...

Patent Primary Examiner

Douglas M Willis

0

Patent abstract

The invention relates to new quinoxaline derivative compounds of formula (I),

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10052320 Substituted quinoxalines as FGFR kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.